/
HCM
$10.71+$0.54 (+5.31%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.7B
172M shares
52-week range
$9.77 – $19.50
10% from low
Exchange
NASDAQ
ADRC
Borrow rate
7.37%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-28.00
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $214.1M | $204.9M | $228.0M | $356.1M | $426.4M | $838.0M | $630.2M | $550.0M |
| Cost of revenue | $143.9M | $160.2M | $188.5M | $258.2M | $311.1M | $384.4M | $348.9M | $337.2M |
| Gross profit | $70.2M | $44.7M | $39.5M | $97.9M | $115.3M | $453.6M | $281.3M | $212.7M |
| Gross margin | 32.8% | 21.8% | 17.3% | 27.5% | 27.0% | 54.1% | 44.6% | 38.7% |
| R&D | $115.6M | $91.9M | $111.2M | $207.4M | $267.6M | $303.1M | $213.4M | $164.1M |
| Operating income | −$92.6M | −$152.8M | −$198.6M | −$328.3M | −$409.8M | $18.4M | −$43.7M | −$54.7M |
| EBITDA | −$82.1M | −$135.1M | −$190.6M | −$208.0M | −$401.1M | $26.6M | −$31.4M | −$41.4M |
| Net income | −$74.8M | −$106.0M | −$125.7M | −$194.6M | −$360.8M | $100.8M | $37.7M | $458.1M |
| Net margin | -34.9% | -51.7% | -55.2% | -54.7% | -84.6% | 12.0% | 6.0% | 83.3% |
| EPS (diluted) | -0.55 | -0.80 | -0.90 | -1.25 | -2.15 | 0.60 | 0.22 | 2.60 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $620M | $0.25 | $0.18–$0.35 | 4 |
| 2027 | $705M | $0.37 | $0.18–$0.71 | 4 |
| 2028 | $798M | $0.56 | $0.51–$0.66 | 3 |
| 2029 | $1.1B | $0.88 | $0.80–$1.03 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
HUTCHMED (China) Limited American Depositary Shares
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
www.hutch-med.com- Employees
- 1,796
- IPO / List date
- Mar 17, 2016
Held by traders on TradeandTell
No one on the platform currently holds HCM.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 132,062 | $2.0M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2009-04-20 | 1-for-50reverse |
Recent trades on TradeandTell
No one on the platform has traded HCM yet.
